UTHR · XBRL financial data

United Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (UTHR's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	609	615*	678	715	749	736*	794	799	800	790*	782	783
Cost of goods and services sold	70	71*	73	78	83	76*	93	88	101	103*	133	100
Gross profit	539	544*	605	637	666	660*	702	711	699	687*	648	684
Research and development	85	151*	104	140	104	134*	149	134	128	140*	138	146
Selling, general and administrative	128	132*	144	178	219	169*	170	213	183	191*	184	207
Operating income (loss)	327	260*	356	320	343	358*	383	365	389	357*	326	331
Interest income	45	51*	54	46	50	49*	51	51	46	43*	42	32
Interest expense	16	15*	13	12	10	8*	6	7	3	3*	3	3
Other income (expense)	(5)	(1)*	2	1	6	(3)*	(4)	(0)	6	47*	(46)	13
Income tax expense (benefit)	84	78*	92	77	80	95*	101	99	99	80*	43	40
Net income (loss)	268	217*	307	278	309	301*	322	310	339	364*	275	333
Earnings per share, basic USD per share	5.71	4.61*	6.52	6.26	6.93	6.72*	7.18	6.86	7.73	8.39*	6.32	7.82
Earnings per share, diluted USD per share	5.38	4.34*	6.17	5.85	6.39	6.22*	6.63	6.41	7.16	7.68*	5.82	7.27
Weighted average shares, basic millions of shares	47	47*	47	44	45	45*	45	45	44	43*	44	43
Weighted average shares, diluted millions of shares	50	50*	50	48	48	48*	49	48	47	47*	47	46

Fiscal quarters (UTHR's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1,108	1,208	1,252	1,356	1,554	1,697	1,900	1,593	1,340	1,557	1,280	1,803
Marketable securities	1,768	1,786	1,456	1,616	1,773	1,570	1,421	1,456	1,428	1,363	874	859
Marketable securities, non-current	2,061	1,910	1,492	1,330	1,279	1,475	1,711	1,918	1,567	1,777	1,317	1,141
Accounts receivable	259	279	307	291	342	279	322	379	298	350	312	310
Inventory	104	112	120	137	147	158	165	169	177	183	178	194
Total current assets	3,459	3,551	3,249	3,620	4,000	3,874	3,940	3,827	3,494	3,703	2,872	3,484
Property and equipment, net	992	1,045	1,074	1,095	1,157	1,222	1,303	1,362	1,556	1,730	1,841	1,930
Goodwill	—	34	—	—	—	32	—	—	—	32	—	—
Total assets	7,024	7,167	6,495	6,723	7,123	7,364	7,744	7,908	7,351	7,880	6,714	7,220
Accounts payable	—	6	—	—	—	6	—	—	—	7	—	—
Accrued liabilities	—	292	—	—	—	339	—	—	—	481	—	—
Total current liabilities	744	804	861	832	873	738	722	527	546	561	599	608
Total liabilities	1,312	1,182	1,157	1,026	1,022	920	937	734	761	784	813	820
Retained earnings	5,810	6,027	6,334	6,612	6,921	7,222	7,544	7,854	8,193	8,557	8,832	9,165
Total stockholders' equity	5,712	5,985	5,338	5,697	6,101	6,444	6,807	7,174	6,590	7,096	5,901	6,400
Total liabilities and equity	7,024	7,167	6,495	6,723	7,123	7,364	7,744	7,908	7,351	7,880	6,714	7,220
Common shares outstanding (cover page) millions of shares	47	47	44	44	45	45	45	45	43	44	42	43

Fiscal quarters (UTHR's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	268	217*	307	278	309	301*	322	310	339	364*	275	333
Stock-based compensation	21*	17*	26	50*	42*	27*	32	38*	39*	39*	34	43*
Depreciation and amortization	13*	14*	15	19*	19*	20*	20	21*	22*	23*	23	24*
Net cash from operating activities	346*	151*	377	232*	377*	341*	461	192*	562*	346*	463	314*
Purchases of property and equipment	66*	79*	38	45*	77*	87*	75	62*	211*	173*	101	108*
Net cash from investing activities	(313)*	42*	735	(80)*	(115)*	(123)*	(165)	(300)*	141*	(228)*	744	88*
Share repurchases	0*	0*	1,000	0*	0*	0*	0	0*	1,000*	0*	1,500	0*
Net cash from financing activities	8*	(93)*	(1,068)	(48)*	(64)*	(75)*	(94)	(199)*	(956)*	98*	(1,484)	122*
Net change in cash	40*	100*	44	104*	198*	143*	203	(307)*	(253)*	217*	(277)	524*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
United Therapeutics	1,189	833	not reported	42.6M	—	Q3 FY26 10-QSep 30, 2026
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
BeOne Medicines	5,098	1,705	463*	1.5B	—	Q2 FY26 10-QJun 30, 2026
Teva Pharmaceutical Industries	4,085	4,395	241	1.2B	—	Q3 FY26 10-QSep 30, 2026
Biogen	1,304	2,804	641*	147.8M	—	Q3 FY26 10-QSep 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.